Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (May 21st Preview)
-
CDx scale-up
Guardant Health won FDA approval for an upgraded Guardant360 Liquid CDx, positioning the test to expand comprehensive tumor profiling beyond the company’s prior assay footprint. Guardant said the new blood-based platform analyzes a genomic footprint 100-fold larger than earlier Guardant360 versions and transfers seven existing FDA-approved CDx indications to the upgraded test.
-
CAR-T M&A and early clinical momentum
Liminatus Pharma agreed to pay shares worth $320 million to acquire InnocsAI, adding an early CAR-T pipeline including IBC101, an autologous CD19xCD22 bivalent program targeting relapsed or refractory B-cell malignancies. InnocsAI already has FDA clearance to begin a Phase 1/2 study in Korea, and the deal also includes a preclinical bicistronic CAR-T concept (INC101) plus an anti-CS1 antibody module intended for a trivalent framework.
-
Genetic medicines delivery
Eli Lilly struck a preclinical acquisition to strengthen non-viral DNA delivery for genetic medicines. Lilly will buy Engage Biologics for up to $202 million, using Engage’s Tethosome platform—a delivery approach that combines engineered DNA payloads with lipid nanoparticles and an mRNA-encoded protein designed to transport material to the cell nucleus.
-
AI in drug discovery platforms
Qiagen and Nvidia expanded their partnership to integrate Nvidia computing and BioNeMo into Qiagen Digital Insights biomedical knowledgebases. Qiagen said the aim is to increase AI use in target selection and biomarker discovery by applying graph-based AI and accelerated compute across its curated discovery platform. Pilot programs are planned first with broader availability expected after validation.
-
Cancer immunotherapy engineering
Researchers reported advances in immune-cell engineering that aim to improve the performance of prime editors. In separate work, structure-informed AI and directed evolution were used to redesign reverse transcriptase domains within prime-editing constructs, with redesigned agents showing improved folding, soluble expression, and editing efficiency in ex vivo contexts and mouse models.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.